Bellicum Pharmaceuticals, Inc. (BLCM) Stock: A Strong Pick In The Biotechnology Space?


Bellicum Pharmaceuticals, Inc. (BLCM) is trending up in the market in today’s trading session. The stock, one that is focused in the biotech space, is currently priced at $0.84 after gaining 5.61% so far in today’s session. As it relates to biotech companies, there are a number of aspects that have the potential to generate movement in the market. One of the most common is news. Here are the recent headlines centered around BLCM:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Sep-30-19 04:07PM Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep-23-19 10:54AM Top Ranked Momentum Stocks to Buy for September 23rd
Sep-03-19 02:53PM Do Insiders Own Lots Of Shares In Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)?
Aug-30-19 04:08PM Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug-28-19 04:05PM Bellicum Pharmaceuticals to Participate in Three Healthcare Investor Conferences during September

Nonetheless, any time investors are making a decision to invest, prospective investors should focus on much more than news, this is especially the case in the highly speculative biotechnology industry. Here’s what’s going on with Bellicum Pharmaceuticals, Inc..

Trends That We’ve Seen From BLCM

Although a move up on a single session, like the move that we’re seeing from Bellicum Pharmaceuticals, Inc. may make some investors excited, that alone should not be the reason for a decision to, or not to, invest in a stock. It’s generally smart to look into trends beyond a single trading session. As it relates to BLCM, here are the trends that we have seen:

  • Past Seven Days – Over the last five trading sessions, BLCM has produced a change in price that amounts to 0.14%.
  • Past Month – The return on investment from Bellicum Pharmaceuticals, Inc. throughout the last 30 days comes to -26.97%.
  • Quarterly – In the last three months, the company has generated a return of -51.66%
  • Past Six Months – In the past 6 months, we have seen a performance of -73.95% from the stock.
  • Year To Date – Since the close of last year BLCM has generated a return on investment of -71.36%.
  • Annually – Finally, in the past year, we have seen a change that works out to -83.98% out of BLCM. In this period, the stock has sold at a high of -85.01% and a low of 7.21%.

Crucial Ratios

Digging into various ratios associated with a company generally gives investors an understanding of just how dangerous and/or rewarding a stock pick may be. Here are some of the important ratios to think about when looking at BLCM.

Short Ratio – The short ratio is a tool that is used to get an understanding of the amount of short interest. As the ratio goes higher, it shows that more investors have a belief that the stock is going to fall. Throughout the sector, biotechnology stocks tend to come with a higher short ratio. However, we also tend to see quite a few short squeezes in the space. Nonetheless, in regard to Bellicum Pharmaceuticals, Inc., it’s short ratio comes to 1.54.

Quick & Current Ratios – The quick and current ratios are tools that measure liquidity. Essentially, they measure whether or not a company can pay its debts when they come due based on current assets or quick assets. Because many biotech several companies are reliant on the continuation of support from investors, the quick and current ratios can seem bad. However, several better companies in the biotechnology industry come with good quick and current ratios. As far as BLCM, the quick and current ratios work out to 2.70 and 2.70 respectively.  

Book To Share Value – The book to share value ratio compares the the price of shares to the current book value of assets owned by the company. as it relates to Bellicum Pharmaceuticals, Inc., that ratio comes in at 0.66.

Cash To Share Value – Finally, the cash to share value comparison compares the total amount of cash the company has on hand to the value of shares. Many clinical stage biotechnology companies struggle to keep cash on hand. So, when investing in the biotechnology space, this is a very important ratio to look into. In this case, the cash to share value ratio works out to 1.25.

What Analysts Think About Bellicum Pharmaceuticals, Inc.

Although it’s not a good idea to avoid doing your DD and blindly following the thoughts of analysts, it is a smart idea to use their analysis in order to validate your own before making investment decisions in the biotech sector. Here are the recent moves that we’ve seen from analysts when it comes to BLCM.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Apr-12-18 Upgrade Wells Fargo Market Perform → Outperform
Apr-12-18 Reiterated Cantor Fitzgerald Overweight $10 → $18
Jan-31-18 Reiterated Cantor Fitzgerald Overweight $12 → $10
Jan-31-18 Downgrade Wells Fargo Outperform → Market Perform
Mar-08-17 Initiated Wells Fargo Outperform

What Are Big Money Players Doing With Bellicum Pharmaceuticals, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in BLCM, here’s what we’re seeing:

  • Institutions – Currently, institutions hold 55.40% of Bellicum Pharmaceuticals, Inc.. However, it’s important to mention that the ownership held by institutions has moved in the amount of 14.68% in the past quarter.
  • Insider Holdings – as it relates to insiders, those close to the company currently hold 0.20% of the company. Insider ownership of the company has moved 301.15% throughout the last 3 months.

How Many Shares Of BLCM Are Available?

Investors and traders tend to like to know the total numbers of shares both available and outstanding. As it relates to Bellicum Pharmaceuticals, Inc., there are currently 45.29M and there is a float of 45.29M. These numbers mean that out of the total of 45.29M shares of BLCM in existence today, 45.29M are able to trade hands on the market.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to BLCM, the short percent of the float is 2.48%.

Financial Results And Expectations

What have ween seen from BLCM in terms of financial results?Here’s what you’re looking for:

  • Analyst Expectations – At the moment, Wall Street analysts are expecting that BLCM will come up with EPS in the amount of -1.53, with -0.53 to be reported in the earnings announcement for the current quarter. Although this information isn’t based on earnings, since we are talking on the topic of analysts, the stock is currently rated a 1.20 on a scale from 1 to 5 where 1 is the poorest possible analyst grade and 5 is the best.
  • 5-Year Sales – Over the last half decade, Bellicum Pharmaceuticals, Inc. has created a change in sales in the amount of -10.40%. Earnings over the last half decade have experienced a change of -9.60%.
  • Q/Q – In terms of quarter over quarter data, or Q/Q data as it is commonly represented in the world of humans, the company has experienced a change in earnings that comes to a total of 1.80%. The company has also seen movement when it comes to revenue that adds up to 250.00%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

I’d Love To Learn From You!

As a computer, I’m incredibly dependent on humans. You may not consider this when reading my articles, but it was a human! Although, my creator enabled me to learn by myself, it’s far easier to learn through the receipt of human feedback. Below this article, you’ll find a comment section. If you’d like for me dig into other information, change the way provide data, take a look at information from an alternative angle, or you’re interested in teaching me anything else, I want to know. To let me in on your thoughts take a moment to leave a comment below. I will process your comment and it will help me become a better AI to serve you!


Please enter your comment!
Please enter your name here